qizi Azamatova et al., 2024 - Google Patents
COMPARATIVE CHARACTERISTICS OF THE MORPHOMETRIC PARAMETERS OF THE KIDNEY IN POLYPHARMACY WITH ANTI-INFLAMMATORY DRUGSqizi Azamatova et al., 2024
View PDF- Document ID
- 13565407449447195675
- Author
- qizi Azamatova D
- et al.
- Publication year
- Publication venue
- SCHOLAR
External Links
Snippet
At the global level, there has been an increase in the number of diseases caused by disorders of the urinary system. The studies were carried out on 250 five-month-old outbred white rats. This article studied changes in the morphometric parameters of the kidney under …
- 210000003734 kidney 0 title abstract description 28
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| qizi Azamatova | COMPARATIVE CHARACTERISTICS OF THE MORPHOMETRIC PARAMETERS OF THE KIDNEY IN POLYPHARMACY WITH ANTI-INFLAMMATORY DRUGS | |
| Green-Sadan et al. | Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats | |
| CN110724203A (en) | A short peptide that promotes nuclear translocation of TFEB and linear short peptide based thereon and its application in reducing cerebral ischemia injury | |
| CN107213149B (en) | Use of artemisinin derivatives in the preparation of medicines for the treatment or adjuvant treatment of autoimmune thyroid diseases | |
| Lukiana et al. | A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy | |
| Mustafo ogli et al. | Comparative Characteristics of the Morphometric Parameters of the Kidney in Polypharmacy with Anti-Inflammatory Drugs | |
| CN110038002B (en) | Use of salvianolic acid A in the prevention and treatment of muscle atrophy, myopathy and musculoskeletal complications | |
| CN116077512A (en) | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| CN107296808B (en) | Application of compound epothilone B in preparation of medicine for repairing corneal nerve injury | |
| CN103948614B (en) | The pharmaceutical applications of otoginsenoside and salt thereof | |
| CN103655545A (en) | Application of jaceosidin in preparation of drugs used for treating or preventing chronic kidney injury | |
| RU2789693C1 (en) | Agent for reduction in pathomorphological manifestations of post-toxic liver cirrhosis and its complications | |
| CN108888756A (en) | The drug of application and both the applications of C16 polypeptide and angiogenin Ang1 | |
| JP2021502952A (en) | How to treat interstitial cystitis | |
| CN1043125C (en) | Artemisia apiacea amber composition for anti toxoplasmagondii | |
| CN112142856B (en) | A specific degrading NDRG2 targeting peptide for improving excitotoxic injury in stroke and its application | |
| Moya et al. | 4CPS-252 Optimisation of ertapenem posology in a critically ill patient by therapeutic drug monitoring: a case report | |
| CN107296804A (en) | A kind of method that topical application β elemenes promote motor function recovery after spinal cord injury | |
| Rodríguez-De Francisco et al. | 4CPS-250 Experience of tecovirimat and cidofovir use in a patient with monkeypox: a case report | |
| CN114010779A (en) | Use and pharmaceutical preparation of anti-NINJ1 antibody in preparing medicine for treating gout | |
| Rakhimovna | DETERMINATION OF THE EFFECT OF RUTAN ON DRUG BIOTRANSFORMATION AND GLUCURONIDATION IN A MODEL OF ACUTE TOXIC HEPATITIS | |
| Saifutdinov | Primary (Isolated) Eosinophilic Colitis. Clinical Case | |
| Arslonova et al. | Evaluation of the Clinical Efficacy of Phenytoin in the Treatment of Epileptic Seizures in Children | |
| Schonwald et al. | Unsuspected quinine intoxication presenting as acute deafness and mutism |